0011980

Roche launches Bluetooth-enabled self-testing device to check blood clotting in EU

pharmafile | May 31, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing HealthTech, Heart Conditions, Roche, blood clotting, product launch 

Swiss drug firm Roche (Six: ROG) has launched a blood-clott monitoring system for patients with different heart conditions.

The CoaguChek INRange system is a Bluetooth enabled home health device that helps patients and their healthcare providers (HCP) monitor coagulation status and the ability to monitor Vitamin K Antagonist (VKA) therapy, the company said in a statement.

Roland Diggelmann, chief operating officer, Roche Diagnostics, said: “As healthcare systems face continued pressure to deliver improved access to care at a lower cost, increased connectivity between HCPs and patients becomes even more important. This innovative technology continues the CoaguChek legacy of setting the standard in coagulation monitoring by providing high quality, convenient care, while optimising outcomes for patients. This is another proof point towards our aim to position patient self-testing as the standard of care to monitor VKA therapy.”

Advertisement

Vitamin K Antagonists (VKAs) are indicated to patients for a variety of conditions, including atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE), and the presence of a mechanical heart valve (MHV).

To best monitor the efficacy of VKAs, the prothrombin time PT (INR) needs to be frequently measured. 

Anjali Shukla

Related Content

alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

blood_test

Roche candidate shows early promise for treating haemophilia A

Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …

Roche advances treatment for Parkinson’s disease

Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, …

The Gateway to Local Adoption Series

Latest content